Compare Gilead Sciences, Inc. (GILD) vs Transocean Ltd (RIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Transocean Ltd — how do they compare? Gilead Sciences, Inc. trades at $147 (market cap $182.09B), while Transocean Ltd trades at $5.57 (market cap $6.02B). The key difference: Gilead Sciences, Inc. is far larger — about 30.2× Transocean Ltd's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Transocean Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Transocean Ltd for 18 Days on average.
| GILD | RIG | |
|---|---|---|
Market Cap | $182.09B | $6.02B |
Volume | 4,960,247 | 19,180,005 |
Sector | Health | Energy |
52-Week High | $155.80 | $7.58 |
52-Week Low | $116.74 | $3.08 |
Typical Hold Time | 111 Days | 18 Days |
Enterprise Value | $205.15B | $10.63B |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $147.10, up 1.99% with bullish technical signals and strong analyst support. The stock shows mixed fundamentals with a P/E of 17.84 and robust gross margins of 79.59%, though recent net income margin turned negative at -10.64%. Recent quarterly earnings beat expectations, and the company announced significant HIV prevention partnerships expanding access to lenacapavir across Latin America.
Outlook remains positive with 65% analyst buy ratings and $151.14 consensus target, though investors face risks from negative profitability metrics and increased investing outflows. The stock's current position near pivot point resistance at $147 suggests potential for breakout if earnings momentum continues.
RIG trades at $5.39, down 0.19% on the day, with a mixed technical picture showing bearish moving averages but neutral oscillators. The company reported a net loss of $2.92 billion in 2025, though revenue remains solid at $3.97 billion. Recent news highlights progress on the $5.8 billion Valaris acquisition and new contract wins, while analyst sentiment is divided with a 39% buy rating.
The outlook hinges on successful deleveraging and offshore cycle strength, but high debt and persistent losses pose significant risks. Investment appeal is speculative, dependent on cash flow improvements and debt reduction outweighing current profitability challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Transocean Ltd
Transocean Ltd. is a leading international provider of offshore contract drilling services for oil and gas wells. The company operates one of the world's most versatile fleets of mobile offshore drilling units, including ultra-deepwater drillships and harsh environment semi-submersibles. RIG's services are essential to energy exploration and production companies seeking to access deepwater and challenging reserves globally.
Read more on RIG →
